Bioscience (25)
Vasolux Microsystems
VasoLux MicroSystems, LLC is developing advanced, optically based, medical devices that will examine many different pathologies in-situ. VasoLux's technology will eliminate waste in the health care system and improve the quality of life for patients by providing physicians with objective and quantitative information regarding specific disease states. This information is invaluable in the determination of the most appropriate therapeutic intervention. VasoLux is a growing, dynamic, and well-funded company composed of experienced medical device entrepreneurs, backed by a strong board of directors and scientific advisory board.
Thermedx, LLC
Thermedx is a novel medical device technology company focused on Fluid Management and Patient Warming. Thermedx is improving the pre-existing practice of Perioperative Fluid Management with its best -in-class Fluid Management System, which is the only FDA 510(k) cleared fluid management device capable of fluid pressure or flow control, on-demand fluid warming, and fluid deficit monitoring.
Thermalin Diabetes Inc
Thermalin Diabetes, LLC is a Cleveland-based biotechnology company developing a portfolio of next generation insulin analogs for both the $8B rapid-acting and the $4B long acting insulin markets. Founded on compounds invented by Dr. Michael Weiss, Chairman of Biochemistry at Case Western Reserve Medical School, Thermalin's therapeutic proteins will address medical needs related to diabetes and its complications.
TheraVasc
TheraVasc, Inc. is a privately held Cleveland, OH corporation which is developing repurposed drugs for new applications. Its first product targets patient populations with poor blood flow to the extremities, such as those suffering from peripheral artery disease (PAD). In the U.S., 16 - 19 million people suffer from PAD but no effective treatments are currently available.
Surgical Theater
Surgical Theater develops Surgery Rehearsal Platforms (SRP) for a patient specific, virtual surgery theater. The SRP transforms medical imagery (e.g. CT) into dynamic and interactive 3D models with life-like tissue interaction and accurate modeling of surgery tools. The SRP allows surgeons to plan and rehearse toward their patient specific case. The virtually operated organ reacts realistically to actions taken by the surgeon, thereby allowing accurate pre-surgery rehearsal, permitting the surgeons to "pre-live the future" of their cases.
Website: http://www.surgicaltheater.net/
SPR Therapeutics
SPR™ Therapeutics is commercializing a novel therapy for severe pain with its patented peripheral nerve stimulation products. The company's pipeline of neurostimulation pain therapies will exploit the same physiologic mechanism of action, proprietary technology and clinical approach.
The first product to be commercialized is the SMARTPATCH™ PNS System, which is a short-term, minimally invasive system that is simple to deliver and can be used for up to 30 days to stimulate electrically a peripheral nerve to relieve pain.
Website: www.sprtherapeutics.com
SpiroSano
SpiroSano is a patent pending technology platform focused on radically changing the way healthcare is delivered for patients with chronic respiratory conditions, such as asthma and COPD, while significantly reducing the associated costs. As a clear differentiator, SpiroSano is the only doctor driven, patient focused, device agnostic and disease specific solution available today in the respiratory space.
The company provides an end-to-end infrastructure for physicians to prescribe personalized and condition-specific kits, receive and analyze the resulting data, and manage the condition via alerts, patient engagement, and data-driven treatments. For example, through the SpiroSano platform, a pulmonologist could prescribe a patient to track a personalized set of parameters such as lung capacity, blood oxygenation levels, activity levels and medication usage. The patient records the parameters through the use of devices such as spirometers, pulse oximeters, adherence monitoring solutions and activity trackers. When the patient uses the devices in the kit, the doctor gains access to the patient’s real-time data through SpiroSano's HIPAA-compliant framework, allowing the doctor to monitor and manage the patient’s condition. Ultimately this will improve patient care by fast-tracking the patient’s path to controlled Asthma or managed COPD, and reduce costs via these gained efficiencies.
SpiroSano received a $100,000 Innovatyion Fund in December 2014.
Sequentia Corporation
Sequentia Corporation has created a web-based, real-time platform for the healthcare industry that improves and streamlines the process of transitioning an individual from the hospital to their next phase of care. The Sequentia Discharge Planning & Placement System™ connects health systems and consumers—from in-hospital patients to at-home individuals and family members—with the optimal provider of extended care services found in the following types of providers: Skilled Nursing, Short-Term Rehabilitation, Long-Term Care, Assisted Living, Independent Living, Alzheimer’s/Dementia, Alcohol & Drug Rehab, Mental Health Care, In-Home Health Care and Hospice. The platform provides improved efficiencies and effectiveness for the discharging hospitals, the patients and the extended care facilities receiving and admitting the patients.
The company received an Innovation Fund award in February 2014.
Website: sequentiacare.com
Rhino Systems, Inc
RhinoSystems, Inc. (RSI) is the developer of the Naväge® Nasal Hygiene System, the world's first handheld nasal irrigator that uses gentle suction. Established in 2007, RSI focuses on bringing innovative products to the market for improved nasal hygiene. RSI owns numerous patents and trademarks worldwide.
RSI is committed to maintaining the highest quality standards so that our products meet the needs of our customers and the expectations of our stakeholders. RSI is certified to ISO 13485:2003, the internationally recognized standard for medical device manufacturing. RSI is registered with the US FDA and the Naväge Nose Cleaner has been cleared by the FDA for commercial distribution in the US.
Website: https://www.navage.com/
Poly MedTech
Poly MedTech creates polymer-based wound closure solutions for the surgical wound closure market. Its initial product allows the surrounding skin to bend and flex ensuring better wound closure and the company is creating a wound closure kit to optimize and simplify the application. Poly MedTech's goal is to reduce the pain and application process associated with sutures and staples.
The company received an Innovation Fund grant in November 2012 and is using the funding to optimize the polymer and begin FDA approval.
Follow Us
